by Gary Cooke | Nov 20, 2019 | News
Month: November 2019 Dr Ben Fenby joins Thirty Group as Chief Development Officer, effective Jan 6, 2020, from an oncology biotech where he was responsible for the late stage portfolio development and strategy. Prior to this Ben worked at AstraZeneca for ten years in... by Gary Cooke | Oct 4, 2019 | News
Thirty Holdings announces the formation of 30Innovation, a wholly owned subsidiary to advance early stage research in biomaterial innovation and new modalities to harness 30Technology™ across Regenerative Medicine, Respiratory and Infectious Disease.... by Gary Cooke | Jul 2, 2019 | News
Jenny Howell joins Thirty Group as Chief Operating Officer. Jenny has more than 20 years’ experience in the biotech and pharmaceutical industry, most recently with AstraZeneca/MedImmune where she held a number of senior leadership positions including Chief of Staff to... by Gary Cooke | Jun 25, 2019 | News, Uncategorised
Thirty Group is delighted to announce the opening of its new Research Centre at Milton Park, Oxford. The facility will house clinical, research, development and regulatory activities for our revolutionary 30Technology™ across Regenerative Medicine, Respiratory and... by 30 Technology | Nov 1, 2018 | News
Thirty Holdings Limited completed a £25 million equity investment led by Morningside Ventures, a major investor in the global Life Science sector. The investment enables the Group to accelerate research and development. We are delighted to welcome Isaac Cheng to the... by 30 Technology | Oct 1, 2018 | News
Thirty Holdings Limited established following a corporate restructure. The Company trading name will be 30 Technology with the name derived from the molecular weight of nitric oxide (30). Edixomed Limited is now a wholly owned subsidiary of Thirty Holdings, focusing...
Recent Comments